RIO DE JANEIRO, BRAZIL - Until a few weeks ago, the Russian Sputnik V vaccine was a distant possibility for much of Latin America in the fight against Covid-19. Brazil and Chile were betting on the Coronavac, the Chinese Sinovac pharmaceutical company's immunizer.
Peru had its eye on the Sinopharma laboratory. Mexico became one of the first countries in the world to close a deal with Pfizer and begin its vaccination campaign. Argentina was one of the few that advanced negotiations for the Sputnik V, which according to a study published on Tuesday in the renowned The Lancet scientific . . .